[{"from": "human", "value": "What can you tell me about this molecule? [C][C@H1][/C][=C][/C][=C][/C][=C][/C][=C][/C][=C][/C][=C][/C][=C][/C@@H1][Branch2][Branch2][N][C][C@H1][C@@H1][Branch2][#Branch1][#Branch2][C@H1][Branch2][#Branch1][Branch1][C][C@][Branch1][Ring2][O][Ring1][=Branch1][Branch2][=Branch1][#Branch2][C][C@H1][Branch2][=Branch1][Ring2][C][C@H1][Branch2][Branch1][=C][C][C@H1][Branch2][Branch1][Branch2][C][C@H1][Branch2][Branch1][C][C][C][=Branch1][C][=O][C][C@H1][Branch2][Ring2][#Branch1][C][C][=Branch1][C][=O][O][C@@H1][Ring2][Ring2][=Branch2][C@@H1][Branch1][C][C][C][C][C][Branch2][Ring1][C][C][C][=Branch1][C][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][O][O][O][O][O][O][O][O][C][=Branch1][C][=O][N][C][C][N][Branch1][C][C][C][O][C@H1][C@H1][Branch2][Ring1][#Branch2][C@H1][Branch1][N][C@@H1][Branch1][Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][C][O][N][C][=Branch1][C][=O][C][N][Branch1][C][C][C][O]"}, {"from": "gpt", "value": "The molecule has been used in trials studying the treatment of Cryptococcosis or Aspergillosis Infections. Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B."}]